Repotrectinib for ALK, ROS1, or NTRK1-3 Alterations

Repotrectinib for ALK, ROS1, or NTRK1-3 Alterations

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is now recruiting. Learn more about enrolling here.

Description
The purpose of this study is to test the safety and efficacy of the investigational drug called repotrectinib in children whose cancers have specific genetic changes (in the ALK, ROS1, or NTRK1-3 genes). This is the first study using this drug in children under 12 years of age. Repotrectinib is administered in capsule form or liquid suspension.  

Eligibility and criteria
IRB Number:
20-018288
Clinical trial phase:
Phase I
Phase II
Official title:
A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations (CARE)

What to expect
As a participant in the research, you will:
  • Be given repotrectinib to take in the clinic and at home
  • Complete frequent clinic visits at CHOP
  • Have frequent blood tests, including research blood tests to measure repotrectinib levels (pharmacokinetic studies), hormone levels (in males only), and tests to measure genetic material in your blood
  • Have periodic EKGs and echocardiograms
  • Imaging performed as part of clinical care will be continued
  • Be asked to complete medication diaries
  • Be asked if we can submit previously obtained samples of your tumor to the sponsor; this will not require new biopsy 

Related specialties
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.